Selective inhibition of BET bromodomain epigenetic signalling interferes with the bone-associated tumour vicious cycle (Q39013915)

8 September 2017

Selective inhibition of BET bromodomain epigenetic signalling interferes with the bone-associated tumour vicious cycle (English)

1 reference

8 September 2017

9

Dominique Heymann

1 reference

8 September 2017

François Lamoureux

1

1 reference

8 September 2017

Marc Baud'huin

2

1 reference

8 September 2017

Lidia Rodriguez Calleja

3

1 reference

8 September 2017

Camille Jacques

4

1 reference

8 September 2017

Martine Berreur

5

1 reference

8 September 2017

Françoise Rédini

6

1 reference

8 September 2017

Fernando Lecanda

7

1 reference

8 September 2017

James E Bradner

8

1 reference

8 September 2017

Benjamin Ory

10

1 reference

8 September 2017

language of work or name

English

0 references

publication date

19 March 2014

1 reference

8 September 2017

Nature Communications

1 reference

8 September 2017

5

1 reference

8 September 2017

3511

1 reference

https://scigraph.springernature.com/pub.10.1038/ncomms4511

8 September 2017

0 references

cites work

Osteosarcoma originates from mesenchymal stem cells in consequence of aneuploidization and genomic loss of Cdkn2.

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS4511

Chemotherapy,en bloc resection, and prosthetic bone replacement in the treatment of osteogenic sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS4511

A pooled analysis of bone marrow micrometastasis in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS4511

Molecular biology of bone metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS4511

MYC on the path to cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS4511

Amplification of both c-myc and c-raf-1 oncogenes in a human osteosarcoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS4511

Amplification of the MYC Gene in Osteosarcoma Secondary to Paget's Disease of Bone

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS4511

c-MYC overexpression with loss of Ink4a/Arf transforms bone marrow stromal cells into osteosarcoma accompanied by loss of adipogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS4511

The Role of RUNX2 in Osteosarcoma Oncogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS4511

MicroRNA-34c inversely couples the biological functions of the runt-related transcription factor RUNX2 and the tumor suppressor p53 in osteosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS4511

Correlation of WWOX, RUNX2 and VEGFA protein expression in human osteosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS4511

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS4511

Progress in the development and application of small molecule inhibitors of bromodomain-acetyl-lysine interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS4511

Place your BETs: the therapeutic potential of bromodomains

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS4511

RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS4511

BET bromodomain inhibition as a therapeutic strategy to target c-Myc

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS4511

Targeting MYC dependence in cancer by inhibiting BET bromodomains

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS4511

BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS4511

Sensitivity of human lung adenocarcinoma cell lines to targeted inhibition of BET epigenetic signaling proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS4511

Inhibition of BET bromodomain targets genetically diverse glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS4511

BET bromodomain inhibition of MYC-amplified medulloblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS4511

Selective inhibition of BET bromodomains

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS4511

Reduced argininosuccinate synthetase is a predictive biomarker for the development of pulmonary metastasis in patients with osteosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS4511

Selective inhibition of tumor oncogenes by disruption of super-enhancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS4511

Master transcription factors and mediator establish super-enhancers at key cell identity genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS4511

BET protein function is required for inflammation: Brd2 genetic disruption and BET inhibitor JQ1 impair mouse macrophage inflammatory responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS4511

Zoledronic acid activates the DNA S-phase checkpoint and induces osteosarcoma cell death characterized by apoptosis-inducing factor and endonuclease-G translocation independently of p53 and retinoblastoma status

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS4511

A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS4511

The enhanceosome and transcriptional synergy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS4511

Cooperative DNA binding of the yeast transcriptional activator GAL4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS4511

Regulated expression of the GAL4 activator gene in yeast provides a sensitive genetic switch for glucose repression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS4511

TNF activates calcium-nuclear factor of activated T cells (NFAT)c1 signaling pathways in human macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS4511

Brd4 coactivates transcriptional activation of NF-kappaB via specific binding to acetylated RelA

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS4511

Interleukin-6 inhibits receptor activator of nuclear factor kappaB ligand-induced osteoclastogenesis by diverting cells into the macrophage lineage: key role of Serine727 phosphorylation of signal transducer and activator of transcription 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS4511

Downregulation of osteoblast markers and induction of the glial fibrillary acidic protein by oncostatin M in osteosarcoma cells require PKCdelta and STAT3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS4511

Therapeutic relevance of osteoprotegerin gene therapy in osteosarcoma: blockade of the vicious cycle between tumor cell proliferation and bone resorption

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS4511

A soluble bone morphogenetic protein type IA receptor increases bone mass and bone strength

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS4511

Oncostatin M induces bone loss and sensitizes rat osteosarcoma to the antitumor effect of Midostaurin in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS4511

Direct anti-cancer effect of oncostatin M on chondrosarcoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS4511

RANKL/RANK/OPG: new therapeutic targets in bone tumours and associated osteolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS4511

inferred from DOI database lookup

7 January 2021

based on heuristic

Runx2 and MYC collaborate in lymphoma development by suppressing apoptotic and growth arrest pathways in vivo

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS4511

inferred from DOI database lookup

7 January 2021

based on heuristic

Brd4 maintains constitutively active NF-κB in cancer cells by binding to acetylated RelA

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS4511

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/NCOMMS4511

1 reference

8 September 2017

0 references

1 reference